(Q46930079)

26 December 2017

title

Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib (English)

1 reference

26 December 2017

main subject

MLN-518

1 reference

ChEBI release 2020-05-28

Petr Knesl

1

1 reference

26 December 2017

Dirk Röseling

series ordinal

2

1 reference

26 December 2017

Ulrich Jordis

series ordinal

3

1 reference

26 December 2017

language of work or name

English

0 references

publication date

10 April 2006

1 reference

26 December 2017

published in

Molecules

1 reference

26 December 2017

volume

11

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

286-297

1 reference

26 December 2017

Creative Commons Attribution 4.0 International

copyright license

start time

10 April 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

1 reference

Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family

21 January 2018

1 reference

New cytotoxic and molecular-targeted therapies of head and neck tumors

21 January 2018

1 reference

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3',5'-phosphate phosphodiesterase inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17962760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/11040286

1 reference

26 December 2017

PMC publication ID

6148630

0 references

1 reference

26 December 2017